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Summary
OBJECTIVES: Despite new treatment modalities, cyclo-
phosphamide (CYC) remains a cornerstone in the treatment
of organ or life-threatening vasculitides and connective tis-
sue disorders. We aimed at analysing the short- and long-
term side-effects of CYC treatment in patients with system-
ic autoimmune diseases.
METHODS: Chart review and phone interviews regarding
side effects of CYC in patients with systemic autoimmune
diseases treated between 1984 and 2011 in a single uni-
versity centre. Adverse events were stratified according to
the “Common Terminology Criteria for Adverse Events”
version 4.
RESULTS: A total of 168 patients were included. Cumu-
lative CYC dose was 7.45 g (range 0.5–205 g). Gastro-in-
testinal side effects were seen in 68 events, hair loss oc-
curred in 38 events. A total of 58 infections were diagnosed
in 44/168 patients (26.2%) with 9/44 suffering multiple in-
fections. Severity grading of infections was low in 37/58
cases (63.8%). One CYC-related infection-induced death
(0.6%) was registered. Amenorrhoea occurred in 7/92 fe-
males (7.6%) with 5/7 remaining irreversible. In females
with reversible amenorrhoea, prophylaxis with nafarelin
had been administered. Malignancy was registered in 19
patients after 4.7 years (median, range 0.25–22.25) present-
ing as 4 premalignancies and 18 malignancies, 3 patients
suffered 2 premalignancies/malignancies each. Patients
with malignancies were older with a higher cumulative
CYC dose. Death was registered in 28 patients (16.6%)
with 2/28 probably related to CYC.
CONCLUSIONS: Considering the organ or life-threaten-
ing conditions which indicate the use of CYC, severe drug-
induced health problems were rare. Our data confirm the
necessity to follow-up patients long-term for timely dia-
gnosis of malignancies. CYC side-effects do not per se jus-
tify prescription of newer drugs or biologic agents in the
treatment of autoimmune diseases.
Key words: cyclophosphamide; side effect; autoimmune
disease; scleroderma; vasculitis; systemic lupus
erythematosus
Introduction
Cyclophosphamide (CYC) is used to treat organ or life-
threatening anti-neutrophil cytoplasmic antibodies
(ANCA)-associated vasculitides and connective tissue dis-
eases such as systemic lupus erythematosus (SLE) or
scleroderma (SSc). Despite new immunosuppressive drugs
and biologic agents CYC remains a cost-effective option
to control disease. Accordingly, the current French recom-
mendations for treatment of granulomatosis with poly-
angiitis (GPA) still propose the use of CYC in defined situ-
ations [1]. In contrast to published data, we found a very
positive side-effect profile of CYC. If correctly indicated
and administered in standardised fashion CYC appears to
be well tolerated. To substantiate this perception we de-
cided to analyse the side effects over a long time period
which, in addition to short term side effects, also allows
judging the carcinogenic effects in patients with severe
autoimmune diseases.
Clinical side effects of CYC comprise nausea, vomiting,
anorexia, bone marrow suppression, infection, infertility,
teratogenicity, pneumonitis and malignancies such as
lympho-proliferative disorders, urothelial and skin cancer
[2–4]. Most of these side effects are short in duration and
only few are organ or even life-threatening. Notably, many
of these can be prevented if adequate measures are taken:
Cumulative dose can be drastically reduced if CYC is ad-
ministered in form of IV pulses instead of oral medication.
Systematic addition of 2-mercaptoethansulfonat-natrium
(mesna) prevents bladder cancer [5], and pretreatment with
gonadotropin releasing agents such as nafarelin or freezing
of sperma may preserve fertility [6]. As a rather surprising
fact, these recommendations are ignored in recent studies
published in high ranking journals [7]. In order to better
evaluate the risk/benefit profile of CYC as well as the be-
nefit/costs of different immunosuppressive strategies, we
set out to analyse the data of our own patients over a time
period of 27 years. The study is retrospective in nature;
however, in addition to chart reviews all patients or their
general practitioners were contacted in order to collect and
complement the data.
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Patients and methods
Medical charts of all patients treated with CYC between
April 1984 and December 2011 in the Department of
Rheumatology, Clinical Immunology and Allergology at
the University Hospital of Bern, Switzerland, were re-
viewed, interviews by telephone or e-mail correspondence
with patients and their general practitioners were addition-
ally performed.
Diagnoses were based on the American College of Rheum-
atology (ACR) criteria for rheumatoid arthritis (RA), SLE,
Le Roy criteria for SSc, Dalakas criteria for polymyositis/
dermatomyositis, Sharp criteria for mixed connective tis-
sue disease (MCTD), Criteria from the European-
American-Consensus-Conference from 2002 for Sjögren
syndrome, Mac Adam criteria for polychondritis and
Chapel Hill Consensus Conference of 1992 or current ACR
criteria for vasculitis.
The following parameters were recorded: disease mani-
festation, immuno-suppressive medication, laboratory data,
short- and long-term adverse effects of CYC, cumulative
CYC dosage, route of administration, and mortality. Each
adverse event was stratified according to the “Common
Terminology Criteria for Adverse Events” version 4 (Grade
1 [mild] through 5 [death related to adverse event]) [8].
Regarding infections we assessed the time interval between
the last CYC cycle and infection. We then calculated the
effect of GC therapy and concomitant immunosuppressive
therapy, lymphocyte count and prophylaxis with TMP-
SMX within one month prior to infection. If TMP-SMX
prophylaxis status was not known, it was considered as
not given. Co-morbidities favouring infections such as dia-
betes, renal insufficiency, alcohol abuse and neoplasia were
noted.
Intravenous (IV) CYC pulses were given at doses of 0.6–1
g/m2 of body surface in 3–4 weekly intervals, and daily
oral CYC was prescribed at 1–2 mg/kg/day to be taken as a
single morning dose. Oral CYC was often prescribed until
1999 and thereafter only if IV pulses did not result in re-
mission of disease activity. In these situations mesna was
prescribed in a dose equal to the CYC dose. All IV-patients
received a pre- and post-CYC fluid bolus of a total of two
liters, a pre- and post-CYC dose of Mesna to prevent blad-
der toxicity and antiemetics. After 2003 SLE treatment fol-
lowed the Euro-Lupus-Nephritis-Trial (500 mg each for 6
times, at 2 week intervals) [9].
182 patients were treated with CYC, 14 of these were ex-
cluded from further analysis due to missing information
on cumulative CYC dosage and insufficient data regarding
follow up. The characteristics of the 168 patients analysed
are displayed in table 1. In brief: CYC was prescribed to
induce remission of vasculitis in 89 patients (ANCA as-
sociated and RA vasculitis) or to control connective tissue
diseases in 69 patients (SLE and scleroderma (SSc). Six
small- /medium-sized vessel vasculitides could not be clas-
sified. Route of CYC administration was oral (PO) in 13
patients, PO and IV in a sequential manner in 27 patients
and IV only in the remaining 126 patients. Median cumu-
lative CYC dosage was 7.45 g (range 0.5–205 g).
Statistical analysis
Influencing factors for infection, malignancy, infertility
and death were analysed using multivariate regression ana-
lysis (IBM SPSS Statistics version 21).
Results
We registered a total of 162 adverse events consisting of
nausea in 63 (37.5%), vomiting in 23 (13.6%), hair loss in
38 (22.6%), cytopenia in 38 patients (22.6%) and haem-
orrhagic cystitis in one patient. Nausea and vomiting was
the reason for switching from IV to PO CYC application in
one patient, and it was the reason for termination of CYC
in another. Cytopenia was characterised as lymphopenia in
36 patients and thrombopenia in another two patients. In 27
patients lymphopenia was associated with infection. Sever-
ity of nausea, vomiting, hair loss and cytopenia was clas-
sified as mild to moderate (grade 1 to 2) in in all but one
event. One patient developed haemorrhagic cystitis during
oral CYC treatment (at times before standard mesna pro-
phylaxis). Severity of haemorrhagic cystitis was graded 3.
All of these side effects were temporary in nature and nor-
malised and healed, respectively, without sequelae.
Infections
58 infections in 44 patients were reported (table 2). There
were nine patients with more than one infection: 7 patients
suffered 2 infections, 1 patient suffered 4 infections and an-
other patient suffered 5 infections. 15 of the 58 infections
(25.9 %) were of bacterial, 11 (18.9%) of viral and 5 (8.6%)
of fungal origin; the causative agent was not identified
in the remaining 27 (46.6%) infections. Prophylaxis for
Pneumocystis jirovecii pneumonia (PJP) with TMP-SMX
was prescribed in 20 cases (34.5%).
Pneumonia occurred in 18 patients. 2 were caused by
Pneumocystis jirovecii and 2 by Haemophilus influenza.
One patient suffered from pneumonia of unknown origin
twice, finally with fatal outcome. The two patients suffer-
ing from PJP had no prior prophylaxis with TMP-SMX.
Their lymphocyte counts were 0.5 G/l and 0.3 G/l respect-
ively at the time of infection. Concomitant prednisone
doses of 50 mg and 5 mg, respectively, plus 15 mg of
weekly methotrexate SC in the latter patient were given 1
month prior to infection.
In two cases of upper airway infection the underlying
agents were identified as Staphylococcus aureus and
Streptococcus species, respectively. Viral infections com-
prised Herpes Zoster (8 patients) and Cytomegalovirus
(CMV) (2 patients). Urinary tract infections of any cause
were noted in 6 cases, 3 caused by Escherichia coli. Can-
didosis in 5 patients was oral in 4 and vaginal in one.
One case of severe aphthous stomatitis of unknown agent
was treated with both antifungal and antiviral therapy and
healed.
Sepsis was noted in three patients with two patients having
bacterial, catheter-related sepsis induced by Coagulase
negative Staphylococcus. One patient suffering lethal sep-
ticaemia of unknown origin three months after the last
CYC dose had concomitant treatment with azathioprine
and a lymphopenia of 0.33 G/l. Furthermore he suffered
from prostatic cancer yet had no tumour related immune-
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suppressing therapy. He had not received TMP-SMX pro-
phylaxis. One of the patients with Coagulase negative Sta-
phylococcus catheter-related infection had no other con-
comitant immunosuppressive treatment besides CYC. She
had a lymphopenia of 0.3 G/l and suffered from malnu-
trition because of rapidly progressive systemic sclerosis.
The second patient with coagulase negative staphylococcus
catheter-related infection was under glucocorticoid treat-
ment (prednisone equivalent 10 mg daily) and hydroxy-
chloroquine 200 mg daily. She had a mild lymphopenia of
0.94 G/l.
At time of infection, lymphocyte counts for the entire in-
fection group showed a median value of 0.63 G/l (range
0.18–3.44) and for the subgroups showing median values
for bacterial infections of 0.63 G/l (range 0.18–11.8), for
viral infections a median of 0.29 G/l (range 0.05–1.07), for
fungal infections a median of 0.64 G/l (range 0.52–2.86),
and within the group of unknown origin the median value
was 0.43 G/l (range 0.3–3.44).
In 49 (84.5%) cases of infection, patients received addi-
tional immunosuppressive medication. This consisted of
GC in 34 cases, GC plus any other type of immunosup-
pressive medication (IS) in 14 cases and one patient receiv-
ing IS without GC (i.e., azathioprine). In the group of pa-
tients receiving only additional GC medication one month
prior to infection, we registered lower lymphocyte counts
at time of infection, a shorter duration between last CYC
and infection and a higher median dosage of GC compared
to the group with GC plus IS. Median values for “GC only”
versus “GC plus IS” were: lymphocyte counts 0.54 versus
0.92 G/l, time from last CYC to infection 15 versus 30
days, GC dosage preceding infection 17.5 versus 10 mg/d.
The severity of infections showed a median of two in each
group.
Vasculitis or connective tissue disease (CTD) revealed sim-
ilar rates of infection in each group with 32.2% in vasculitis
(22/69 patients) and 34.8% in CTD (31/89 patients).
Co-morbid conditions possibly favouring infection were
diabetes mellitus in 7 patients, renal insufficiency in 6,
preexistant neoplasia in 1 patient and splenectomy in an-
other. None of the 2 patients with alcohol abuse suffered
infection.
Grading of side effects is summarised in table 3.
Reproductive system
Details are given in table 4. A total of 7/92 (7.6%) women
suffered amenorrhoea at a median age of 35 years of age
(range 21–50) after a mean cumulative CYC dose of 14.4 g
(range 6–40). Amenorrhoea was irreversible in 5/7 and re-
versed in 2/7 women within 2 years after CYC induction.
The latter two patients had been treated prophylactically
with nafarelin, an analogon of gonadotropine-releasing-
hormone (GnRH) started together with the first cyclophos-
phamide pulse. Their cumulative CYC dosages were 7.25
g for SLE at the age of 21 years and 14.4 g for eosinophilic
granulomatosis with polyangiitis (eGPA) at 25 years of
age, respectively.
In the other five women irreversible amenorrhoea deve-
loped after a median cumulative CYC dose of 34.5 g (range
6–40) at a median age of 39 years (range 34–50) treated
Table 1: Patient characteristics.
GenderDiagnosis Number of patients
[%]
Median age at
diagnosis, years
(range)
Female Male
All patients 168 52.7 (7.5–86) 92 (54.7%) 76 (45.2%)
Vasculitis 89 38 51
ANCA associated 51 51.6 22 29
GPA 34 51.1 15 19
MPA 4 50.7 1 3
eGPA 4 55.2 1 3
Others 9 68.2 5 4
Cryoglobulinaemic vasculitis 2 52.1 1 1
Henoch-Schönlein purpura 1 53.9 1
RA associated vasculitis 15 53.3 10 5
Panarteritis nodosa 9 68.5 1 8
Behçet’s disease 3 34.0 1 2
Other small-/medium-sized vessel vasculitis 6 62.0 2 4
Giant cell vasculitis 1 77.4 1
Cogan’s syndrome 1 49.7 1
Polychondritis 1 39.8 1
Connective tissue diseases 69 47 22
SLE 28 39.5 25 3
Diffuse 20SSc
Limited 8
54.8 14 14
Sjögren syndrome 4 53.4 4
Inflammatory muscle disease 2 46.0 2
Mixed connective tissue disease 2 22.9 2
Undifferentiated connective tissue disease 5 49.1 2 3
Autoimmune eye disorders 1 49.1 2
Others 8 59.5 3 4
GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; eGPA = eosinophilic GPA; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; SSc =
systemic sclerosis.
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for miscellaneous autoimmune diseases (small vessel vas-
culitis, systemic lupus erythematosus, granulomatosis with
polyangiitis, scleroderma and undifferentiated polyarthrit-
is).
Azoospermia was reported in 1/76 (1.3%) male patient
with Behçet’s vasculitis after a cumulative CYC dose of 40
g at 33 years of age.
Severity of secondary sterility was classified as grade 3.
Pre-/malignancy
For details see table 5. We registered 22 pre-/malignancies
in 19 patients (12 male, 7 female) with 3 patients suffering
2 pre-/malignancies each. Median age at tumour diagnosis
was 60.75 years (range 43.5–85.5 years). Median time
from first dose CYC to tumour diagnosis was 56 months
(range 3–267 months). Median cumulative dose at time of
malignancy was 10.6 g (range 1.95 to >100 g).
Actinic keratosis, classified as skin premalignancy was dia-
gnosed in 4 cases, 9 of the 18 malignancies were 9 skin
cancers, 8 basaliomas and 1 squamous cell carcinoma
(mean age 76, range 57–85). All skin pre-/malignancies
were successfully treated. Interval between the start of
CYC therapy and diagnosis of skin cancer was less than
four years in two of these patients.
The GPA patient suffering from B-cell lymphoma at the
age of 83.5 years had received a cumulative CYC dose
of 70 g. The neoplasm was diagnosed 22.25 years after
the first CYC dose. He died two months after diagnosis
of lymphoma. A chronic myelomonocytic lymphoma
(CMML) suspected in a 86.5 year old female with RA vas-
culitis occurred only 4 months after initiation of CYC. She
died 3 months after having received a cumulative CYC
dose of 2.3 g. One SLE patient suffering acute myeloid
lymphoma (AML) at the age of 57 is in remission more
than 3 years after diagnosis.
The patient with the adrenal carcinoma had developed mul-
tiple metastases, however, is in remission more than nine
years after diagnosis. The patient with kidney tumour died
of septicaemia three years after diagnosis. The patient with
seminoma has so far been cured by semicastration and
chemotherapy. The urothelial carcinoma was diagnosed
1.08 years after CYC induction only. The chondrosarcoma
was detected three months after the first dose of CYC in an
anti-Hu syndrome. As this rare syndrome is typically asso-
ciated with malignancy, the chondrosarcoma is considered
part of the disease and not caused by CYC [10].
Table 2: Infections.
Lymphopenia* Grade**IS = immunosuppressive medication; TMP-
SMX= trimethoprime-sulfamethoxazole;
Infection type
No GC only
1 month
before
infection
GC plus
IS
1 month
before
infection
Prophylaxis
with TMP-
SMX
Days last CYC to
infection median
(range)
Global
(<1.1
G/l)
≤0.3 G/l 1, 2 3 4 5
Bacterial infections (total) 15 10 5 8
Hidradenitis 1 1 14 1 1
Laryngitis/Pharyngitis 3 3 1 1 25 (14–90) 2 3
Urinary tract 3 2 2 1 30 (13–72) 1 1 2
Bronchial contamination 1 1 20 1
Pneumonia 4 2 2 67.5 (15–120) 3 1 3 1
(out of “Pneumonia”: PCP) 2 1 1 (15– 120)*** 1 1 2
Gastrointestinal infection 1 1 1 9 1 1
Catheter-related infection 2 1 1 1 28.5 (27–30) 1 1 2
Fungal infection (total) 5 4 2 1 17 (13–90)
Candida-Stomatitis/Glossitis 4 3 2 1 22 (13–90) 3 4
Vaginal 1 1 17 1 1
Viral infections (total) 11 5 3 4 14.5 (10–150)
CMV-Infection 2 2 2 2
Herpes zoster 8 2 3 3 14,5 (10–150) 3 2 7 1
Gastrointestinal infection 1 1 1 1 1
Undetermined type (total) 27 15 5 7 24 (9–120)
Infection unknown localization 2 2 1 14 1 1 2
Agranulocytosis 1 1 1 1 1
Upper respiratory tract 1 1 12 1 1
Bronchitis 1 1 14 1 1
Pneumonia 14 5 2 4 24 (14–120) 9 10 2 1 1
Urinary tract infection 3 2 1 1 62 (24–100) 2 2 1
Gastroenteritis 1 1 1 37 1
Perichondritis 1 1 1 1 1
Stomatitis 2 19.5 (14–25) 1 1 2
Otitis 1 1 70 1 1
All 58 34 15 20 34 10 38 15 4 1
* Lymphocyte count unknown in 2 patients with pneumonia, 1 patient with laryngitis/pharyngitis and 1 patient with gastrointestinal infection;
** Grade not known for 1 patient with pneumonia, 1 patient with gastrointestinal infection, 1 patient with perichondritis, 1 patient with herpes
zoster and both patients with CMV-infection, was the reason for stopping CYC therapy in one CMV-patient;
*** Patient had stopped TMP-SMX 3 months before the infection, after completing CYC therapy.
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Mortality
Twenty-eight patients (16.6%) had died, 4 deaths were
infection-related (1 died 3 months after completed CYC
therapy, 3 died more than 6 years after completed CYC
therapy), 10 disease-related (8 SSc, 1 GPA with renal fail-
ure, 1 rheumatoid arthritis), 11 other causes (2 myocardial
infarction, 4 heart failure, 1 pulmonary embolism, 1 respir-
atory failure, 1 cardiac arrest, 1 visceral perforation, 1 as-
sisted suicide), 3 of unknown cause.
One patient with lethal respiratory failure due to infection
had a total treatment period of 6 months IV CYC for rapid
progressive systemic sclerosis (cumulative CYC dosage of
5.5 g). He concomitantly suffered prostatic cancer.
Statistics
Statistical analysis revealed no relevant influence of either
age, sex, type of disease, type of co-medication, co-mor-
bidities or cumulative CYC dosage on incidences of in-
fection, malignancy, infertility or death. In particular there
was no statistical correlation between the infection and the
1–month-preceding lymphocyte count or medication in-
cluding glucocorticoids. Overall regression analysis failed
to give valuable data because of the small sample size with-
in each group.
Table 3: Grading of adverse events.
Adverse events Number (%) Female Male
Grade 1 or 2
Infections 38
Nausea 63 (37.5) 33 30
Vomiting 23 (13.6) 16 7
Hair loss 38 (22.6) 26 12
Cytopenia 38 (22.6) 19 19
Amenorrhoea 7 (7.6)
Grade 3
Secondary sterility 6 5 1
Infections 15
Haemorrhagic cystitis 1 (0.5) 1
Grade 4
Infections 4
Grade 5
Infection 1
Table 4: Characteristics of patients with amenorrhoea.
Amenorrhoea1 Reversible amenorrhoea1 Irreversible amenorrhoea1 No amenorrhoea2
N = 7 N = 2 N = 5 N = 42
Median age
(range)
35 (21–50) 23 (21–25) 37 (34–50) 35 (8–50)
Median cumulative CYC dose,
g (range)
14.4 (6–40) 10.8
(7.25–14.4)
24.45 (6–40) 7.35
(0.5–122.4)
GnRh-analogon yes no no
age
(years)
dose
(g)
age
(years)
dose
(g)
21 7.25 34 36
25 14.4 35 40
39 6
43 34.5
Single patients
50 7.3
1 Age and cumulative CYC dose at onset of amenorrhoea.
2 females <50 years of age
Table 5: Pre-/malignancies.
All Male Median time CYC
to tumour, months
Median time CYC to
tumour, years
Median cumulative CYC
dose, g
Premalignancy 4 1 3
Actinic keratosis 4 1 3 63 (24–76) 5.25 (2–6.33) 30.6 (6–100)
Malignancies 16 4 12
Skin* 9 2 7 60 (24–117) 5 (2–9.75) 10.6 (3.9–70)
Urothelial carcinoma 1 1 13 1.08 9.1
Haematologic** 4 2 2 39.5 (4–267) 3.3 (0.3–22.25) 14 (2.3–70)
Others*** 4 2 2 82 (3–192) 6.8 (0.25–16) 9.1 (2–16)
All 22 7 15 56 (3–267) 4.7 (0.25–22.25) 10.6 (2–100)
* 8 basaliomas, 1 squamous cell carcinoma;
** 1 suspected CMML, 1 secondary AML on myelodysplastic syndrome, 1 smouldering myeloma and 1 diffuse B-cell-lymphoma;
***1 kidney-tumour, 1 seminoma, 1 chondrosarcoma and 1 adrenal carcinoma.
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Discussion
CYC, even in the era of an evolving number of biologics,
still plays an important role in treating autoimmune dis-
eases. This is illustrated by the recent French recommend-
ations to treat ANCA-associated vasculitides, but also by
a comparative work from the European Vasculitis Study
Group [11]. In this study CYC was added to the new biolo-
gic to induce remission and not only used as control med-
ication. Considering the demand for cost-effectiveness one
has to take into account that a standard induction therapy
by a currently used biologic amounts to costs more than 10
times higher when compared to CYC.
Our retrospective analysis of 168 patient charts complemen-
ted by phone interviews with patients and/or their treating
physicians confirms a positive side effect profile of CYC in
the treatment of systemic autoimmune diseases. Most side
effects were mild and transient, very few were severe in
nature [12, 13]. In discussing severe side effects of a drug,
one has to judge them in the context of severity and pro-
gnosis of the disease itself. CYC is used for the treatment
of organ or life-threatening autoimmune diseases. It may,
therefore, be difficult in a given case to precisely determine
respective roles of disease and drug. The fact that only one
patient died as a probable consequence of treatment, but 11
patients as an undisputable consequence of their immune
disease clearly argues for a decisive role of the disease in the
majority of fatal cases, at least in our cohort.
The following side effects need to be discussed in more
detail: Amenorrhoea, infection, malignancy and death.
Regarding amenorrhoea, our data confirm a well-known
age-dependency [14–16]. The two patients with transient
amenorrhoea were at least nine years younger than the five
with persisting amenorrhoea. Based on their family plan-
ning they were treated with GnRH, as has recently been
published with conflicting results [17, 18]. We cannot dis-
tinguish the effect of age from the effect of GnRH. Very
recent data showed that antimullerian hormone levels re-
mained higher in a patient cohort treated with GnRH as
compared to a group without, indicating preservation of
ovarian function by GnRH [19]. Despite some contradict-
ing data, we suggest usage of GnRH starting together with
the first infusion of CYC.
Regarding infections, we calculated effects of GC prescrip-
tion, TMP-SMX prophylaxis, lymphocyte counts and com-
bination therapies on incidence and outcome. Although we
found descriptive differences, they did not reach statistic-
al significance. On the one hand one may argue that popu-
lations were too small to reach statistical significance. On
the other one may conclude that the signals are indeed
very small and, therefore, do not become clinically relev-
ant. Published data show a negative effect of glucocortic-
oids if prescribed beyond six months and at doses as low
as 5 mg per day [20]. Another study reported a negat-
ive impact of IV glucocorticoids and/or immunosuppress-
ants as long-term risk factors for infections [21]. In conclu-
sion, our findings together with published data prompt us to
continue monitoring lymphocyte counts and to reduce GC
doses as soon as clinically feasible.
Data unanimously show increased risks for non-melanoma
skin cancer, leukaemia and urinary tract cancer [22, 23]
with delays up to 18.5 years. Remarkably, a cumulative
dose of 36 g (corresponding to 100 mg/day over 1 year)
did not result in a significant increase of malignoma forma-
tion [23]. An analysis of a cohort of 535 vasculitis patients
showed an increase only in non-melanoma skin cancer
[24]. This finding may primarily be explained by the lower
cumulative CYC doses used today. An intriguing differen-
ce in malignoma incidence was suggested regarding GPA
versus microscopic polyangiitis [22], strongly arguing for a
contributing effect of the underlying autoimmune disease.
In our cohort we found a rather wide spectrum of maligno-
ma, a wide range in cumulative CYC doses and a wide range
in time intervals between initiation of CYC treatment and
diagnosis of the neoplastic diseases. In line with published
data, 13 of 19 tumours were premalignancies or basaliomas/
squamous epithelial carcinomas of the skin. Remarkably, 2
of these developed within 4 years. We registered a total of
four haematological and lymphoproliferative malignomas.
Two of the patients were diagnosed at an age beyond median
life expectancy. Of note, no bladder cancer was diagnosed, a
fact which may be related to the consequent prescription of
mesna even if CYC is taken as an oral medication. The other
malignomas such as adrenal carcinoma or seminoma do not
have a clear association with CYC.
A weakness of the study is its retrospective nature. Al-
though we recovered many previously lost data by phone
interviews, it is likely that we missed patients and side ef-
fects. Yet, there is no obvious bias in data acquisition. Per-
centages, types and severity of side effects would probably
not have changed. An advantage of our study is that we re-
port data of a single academic centre. This allows judge-
ment of standard operation procedures and may underline
certain published recommendations. Finally, in contrast to
randomised controlled trials which study well character-
ised, however, highly selected patients, retrospective stud-
ies report on everyday situations, including patients with
unfavourable disease profiles at very high treatment risks.
In summary, we could confirm our hypothesis that CYC –
used in the recommended doses and administered in stand-
ardised fashion – shows a surprisingly positive side-effect
profile. The data strongly argue for an individualised and
differentiated use of either CYC or one of the newer drugs/
biologic agents. The fact that malignoma were diagnosed
after short intervals and at low cumulative doses asks for a
vigilant eye on the development of any kind of neoplastic
disease throughout the whole patient history, in particular
in situations of lasting remission.
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